Data from Incytes TGFR2PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFR2PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally...